Navigation Links
VEGFR2 in Medical News

Clinical studies in the pipeline: the therapies of tomorrow in trials today

...itinib is a receptor tyrosine kinase inhibitor designed to target and block vegfr2 activity, among other pro-growth molecules. To find out if sunitinib co...ors found that the levels of VEGF and PIGF increased, while that of soluble vegfr2 declined in most patients. Also, flow cytometry analyses of blood cells sug...
VEGFR2 in Medical Technology

Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2

PALO ALTO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) reported positive preclinical data from its ongoing program to develop novel small molecule inhibitors of validated cancer targets including aurora kinases and VEGFR2. The data were presented today at the AACR-NC...

Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2

PALO ALTO, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) announced that preclinical data from its program to develop novel small molecule kinase inhibitors will be presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in San Francisco....

New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models

...ctive agents such as Avastin block binding to both vegfr2 and VEGF receptor 1 (VEGFR1). Selective anti-VEGF ...r tissue. Dr. Brekken commented, "VEGF binding to vegfr2 on blood vessels is a primary driver in promoting ... tested the hypothesis that selectively inhibiting vegfr2 is an equally effective anti-tumor strategy as blo...

Interim Phase 2 Data for Exelixis' XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer

...raging data from an ongoing phase 2 trial of XL880, an inhibitor of MET and vegfr2 kinases, in patients with papillary renal cell carcinoma (PRC). Of 19 patie...otential utility of XL880 and its potent effects in modulating both MET and vegfr2 in the clinical setting. We are excited about the potential therapeutic uti...

New Data for XL880, XL647 and XL184 to Be Presented at AACR-NCI-EORTC

...lar Targets and Cancer Therapeutics, which will be held October 22-26, 2007 in San Francisco. In addition, phase 1 data for XL184, which inhibits MET, vegfr2 and RET, will also be presented. In total, 13 abstracts for eight compounds have been accepted for poster presentation at the conference, reporting da...

Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine and Seliciclib at AACR

... nucleoside analog, is in Phase I clinical trials for the treatment of solid and hematological cancers. CYC116, an orally-available, Aurora kinase and vegfr2 inhibitor, is at the IND stage. Several additional programs are at an earlier stage. About seliciclib Seliciclib is an orally-available cyclin dep...

Data Presented at AACR Meeting Shows Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models

...of studies reported today tested the hypothesis that selectively inhibiting vegfr2 is an equally effective anti-tumor strategy to blocking both receptors. Mos...od, 2C3 produced decreased microvessel density, decreased expression of the vegfr2 receptor and decreased tumor-associated macrophage invasion, which was cons...

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

...ere observed and considered possibly related to XL880. "We believe these results clearly demonstrate that XL880 simultaneously inhibits both MET and vegfr2 in this clinical setting," said Michael M. Morrissey, Ph.D., president of research and development at Exelixis. "Inhibition of both MET and VEGFR2 abr...
VEGFR2 in Biological News

Axel Ullrich named winner of 2009 Dr. Paul Janssen Award for Biomedical Research

...ptor or VEGFR) suppresses the generation of blood vessels in tumors and slows down cancer cell growth. Years later, a small molecule inhibitor of the vegfr2 kinase function was developed, from which a derivative was approved in 2006 for the treatment of kidney carcinoma and gastro-intestinal stromal tumors...

Synthetic molecules may be less expensive alternative to therapeutic antibodies, researchers find

... a type of molecule on the surface of human cells. vegfr2 is essential in creating new blood vessels through...o tiny plastic beads. In the study, the cells with vegfr2 were labeled to fluoresce red and those lacking vegfr2 were labeled to fluoresce green. After exposing th...
VEGFR2 in Biological Technology

Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech

...tinctive because it selectively blocks VEGF from binding to VEGF receptor 2 (VEGFR2), while non-selective agents such as Avastin block binding to both vegfr2 and VEGF receptor 1 (VEGFR1). Selective anti-VEGF agents such as r84 may have safety and efficacy advantages over non-selective approaches. In addit...

Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research

...eptor or VEGFR) suppresses the generation of blood vessels in tumors and slows down cancer cell growth. Years later, a small molecule inhibitor of the vegfr2 kinase function was developed, from which a derivative was approved in 2006 for the treatment of kidney carcinoma and gastro-intestinal stromal tumors...

REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO

...662164. ASCO Presentations Saturday, May 31 -- XL647 (EGFR, HER2, VEGFR2) -- Poster & Discussion "A phase 1 study of XL647, an EGFR, HER2, vegfr2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM)" Day: Saturday, May 31 Session: Developm...

Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing

.... ASCO Presentations Saturday, May 31 -- XL647 (EGFR, HER2, VEGFR2) -- Poster & Discussion "A phase 1 study of XL647, an EGFR, HER2, vegfr2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM)" Day: Saturday, May 31 Sessi...

Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research

...fective as an anti-cancer therapy. Through the use of Telik's Target-Related Affinity Profiling (TRAP(R)) screening technology, novel inhibitors of vegfr2 kinase were discovered. The inhibitors belong to nine structural classes, among which E2B8 and EAAF are sub-micromolar inhibitors of the kinase. M...
VEGFR2 in Biological Products
Other Tags
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax accounting ... consulting services in addition to a variety of other ... planning. Company finances are a complicated matter that should ... this, complex Canadian tax laws can make it even ... Mew and Company works to advise their clients on ...
(Date:2/28/2015)... Indosoft Inc , developers of ... are pleased to announce the development of Q-Suite 5.9. ... versions of Q-Suite, this new version will include enhancements ... new features to the leading edge call center software. ... will add features to enhance security and protection. Administrators ...
(Date:2/28/2015)... For those people who are unable to ... Applied Research Foundation (Meso Foundation) will broadcast its ... at 9:30 AM. , The live broadcast is free ... be accessed through any browser on a computer or ... is a unique event that covers important treatment information ...
(Date:2/28/2015)... Pioneer Millworks reclaimed USA wood will be on ... Show, an annual, premier sustainable building event in Tokyo, ... manufacturers of the latest building products, services and technology. ... manufactured by Pioneer Millworks from their Oregon and New ... hotels, retailers, and corporate offices. Nichibi Global , ...
(Date:2/28/2015)... Pismo Beach, CA (PRWEB) February 28, 2015 ... the needs of Central Coast area residents, recently announced ... Whitening System. It’s a treatment option for new ... patients kick off 2015 with a bright, white smile, ... the discounted price of $299, marked down from the ...
Breaking Medicine News(10 mins):Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2
Other Contents